Targeting interleukin-6 in rheumatoid arthritis

Drugs

Volumn 73, Issue 4, 2013, Pages 341-356

  Md Yusof, Md Yuzaiful ^a   Emery, Paul ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLAZAKIZUMAB; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; OLOKIZUMAB; PLACEBO; SARILUMAB; SIRUKUMAB; TOCILIZUMAB;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; COMORBIDITY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LIPID BLOOD LEVEL; PATHOGENESIS; REVIEW; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; HUMANS; INTERLEUKIN-6; MOLECULAR TARGETED THERAPY; RECEPTORS, INTERLEUKIN-6; TREATMENT OUTCOME;

EID: 84878843826     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0018-2     Document Type: Review

References (84)

1. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am. 2001;27(2):269-81.
2. Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol. 2003;21(5):S154-7.
3. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;22:1586-93.
4. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study - a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26-37.
5. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675-81.
6. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516-23.
7. Srirangan S, Choy EH. The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2010;2(5):247-56.
8. Hibi M, Murakami M, Saito M, et al. Molecular-cloning and expression of an IL-6 signal transducer, GP130. Cell. 1990;63(6):1149-57.
9. Taga T, Hibi M, Hirata Y, et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, GP130. Cell. 1989;58(3):573-81.
10. Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5(12):1731-40.
11. Rose-John S, Scheller J, Elson G, et al. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006;80(2):227-36.
12. Muraguchi A, Hirano T, Tang B, et al. The essential role of B-cell stimulatory factor-II (BSF-2/IL-6) for the terminal differentiation of B-cells. J Exp Med. 1988;167(2):332-44.
13. Hashizume M, Mihara M. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis. 2011;2011:765624.
14. Zhou L, Ivanov II, Spolski R, et al. IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8(9):967-74.
15. Madhok R, Crilly A, Watson J, et al. Serum interleukin-6 levels in rheumatoid arthritis - correlations with clinical and laboratory indexes of disease activity. Ann Rheum Dis. 1993;52(3):232-4.
16. Sack U, Kinne R, Marx T, et al. Interleukin-6 in synovial-fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol Int. 1993;13(2):45-51.
17. Maruotti N, Cantatore FP, Crivellato E, et al. Angiogenesis in rheumatoid arthritis. Histol Histopathol. 2006;21(4-6):557-66.
18. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93(2):165-76.
19. Palmqvist P, Persson E, Conaway HH, et al. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol. 2002;169(6):3353-62.
20. Ohta S, Imai K, Yamashita K, et al. Expression of matrix metalloproteinase 7 (matrilysin) in human osteoarthritic cartilage. Lab Investig. 1998;78(1):79-87.
21. Okada Y, Gonoji Y, Nakanishi I, et al. Immunohistochemical demonstration of collagenase and tissue inhibitor of metalloproteinases (TIMP) in synovial lining cells of rheumatoid synovium. Virchows Arch B Cell Pathol Incl Mol Pathol. 1990;59(5):305-12.
22. Chrousos GP. Seminars in medicine of the Beth-Israel-Hospital, Boston - the hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332(20):1351-62.
23. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102(3):783-8.
24. Yoshio-Hoshino N, Adachi Y, Aoki C, et al. Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Res. 2007;67(3):871-5.
25. Kaly L, Rosner I. Tocilizumab - a novel therapy for non-organ-specific autoimmune diseases. Best Pract Res Clin Rheumatol. 2012;26(1):157-65.
26. Burmester GR, Rubbert-Roth A, Cantagrel AG, et al. A randomized, double-blind, parallel group study of the safety and efficacy of tocilizumab SC versus tocilizumab IV, in combination with traditional Dmards in patients with moderate to severe RA. Arthritis Rheum. 2012;64(10):S1075.
27. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54(9):2817-29.
28. Smolen JS, Schoels M, Nishimoto N, Breedveld FC, Burmester G, et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis. Epub 30 Jan 2013.
29. Matsuyama M, Suzuki T, Tsuboi H, et al. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease. Int Med. 2007;46(11):771-4.
30. Seitz M, Reichenbach S, Bonel HM, et al. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. Swiss Medical Wkly. 2011;141:w13156.
31. Unizony S, Arias-Urdaneta L, Miloslavsky E, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res. 2012;64(11):1720-9.
32. Puechal X, de Bandt M, Berthelot J, et al. Tocilizumab in refractory adult Still's disease. Arthritis Care Res. 2011;63(1):155-9.
33. Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62(2):542-52.
34. Sumida K, Ubara Y, Suwabe T, et al. Complete remission of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody. Rheumatology. 2011;50(10):1928-30.
35. Shapiro LS, Farrell J, Haghighi AB. Tocilizumab treatment for neuro-Behcet's disease, the first report. Clin Neurol Neurosurg. 2012;114(3):297-8.
36. Hirano T, Ohguro N, Hohki S, et al. A case of Behcet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol. 2012;22(2):298-302.
37. Shima Y, Kuwahara Y, Murota H, et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology. 2010;49(12):2408-12.
38. Narazaki M, Hagihara K, Shima Y, et al. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology. 2011;50(7):1344-6.
39. Genovese MC, Kivitz AJ, Simon Campos AJ, et al. Sarilumab for the treatment of moderate-to-severe rheumatoid arthritis: results of a phase 2, randomized, double-blind, placebo-controlled, international study. Arthritis Rheum. 2011;63(12):4041-2.
40. Mease P, Strand V, Dimic A, et al. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis. 2012;71(7):1183-9.
41. Hsu B, Sheng S, Smolen JS, et al. Results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-interleukin-6 monoclonal antibody, in active rheumatoid arthritis patients despite methotrexate therapy. Arthritis Rheum. 2011;63(10)
42. Fleischmann R, Kivitz AJ, Wagner F, et al. A pilot study investigating the tolerability and pharmacodynamic effect of single intravenous/subcutaneous doses of olokizumab, an anti-interleukin-6 monoclonal antibody, in patients with rheumatoid arthritis. Arthritis Rheum. 2012; 64(10).
43. Nishimoto N, Kazuyuki Y, Nobuyuki M, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody - a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50(6):1761-9.
44. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88-96.
45. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19(1):12-9.
46. Dougados M, Kissel K, Conaghan PG, et al. Clinical, radiographic, and immunogenic effects after 1 year of tocilizumab-based treatment strategy with and without methotrexate in rheumatoid arthritis: the ACT-RAY study. Arthritis Rheum. 2012;64(10):S1077-8.
47. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66(9):1162-7.
48. Nishimoto N, Miyasaka N, Yamamoto K, et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2009;68(10):1580-4.
49. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987-97.
50. Yazici Y, Curtis JR, Ince A, et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis. 2012;71(2):198-205.
51. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968-80.
52. Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011;63(3):609-21.
53. Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796-806.
54. Mierau M, Schoels M, Gona G, et al. Assessing remission in clinical practice. Rheumatology. 2007;46(6):975-9.
55. Dinarello CA, Cannon JG, Wolff SM, et al. Tumor-necrosis-factor (cachectin) is an endogenous pyrogen and induces production of interleukin-1. J Exp Med. 1986;163(6):1433-50.
56. Brennan FM, Jackson A, Chantry D, et al. Inhibitory effect of TNF-alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 1989;2(8657):244-7.
57. Gaujoux-Viala C, Mouterde G, Baillet A, et al. Evaluating disease activity in rheumatoid arthritis: Which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI. Joint Bone Spine. 2012;79(2):149-55.
58. Matsui T, Kuga Y, Nishino J, et al. Comparison of composite disease activity indices for rheumatoid arthritis. Mod Rheumatol. 2011;21(2):134-43.
59. Kaneko A, Kida D, Saito K, et al. Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI. Rheumatol Int. 2012;32(11):3631-7.
60. Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum. 2011;63(1):43-52.
61. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315-23.
62. Takayanagi H, Iizuka H, Juji T, et al. Involvement of receptor activator of nuclear factor kappa B ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2000;43(2):259-69.
63. Conaghan PG, Peterfy CG, DiCarlo J, et al. Early reductions in tissue inflammation with tocilizumab as either monotherapy or in combination with methotrexate: 12-week unblinded results from a magnetic resonance imaging substudy of a randomized controlled trial. Arthritis Rheum. 2011;63(10):S165-6.
64. Fries JF, Ramey DR. ''Arthritis specific'' global health analog scales assess ''generic'' health related quality-of-life in patients with rheumatoid arthritis. J Rheumatol. 1997;24(9):1697-702.
65. Ramey DR, Raynauld JP, Fries JF. The health assessment questionnaire 1992: status and review. Arthritis Care Res. 1992;5(3):119-29.
66. Schiff MH, Kremer JM, Jahreis A, et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011;13(5):R141.
67. Kobayashi K, Okamoto Y, Inoue H, et al. Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA). Int Med. 2009;48(15):1307-9.
68. Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology. 2011;50(3):552-62.
69. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials [published erratum appears in JAMA 2006;295(21):2482]. JAMA. 2006;295(19):2275-85.
70. Suwa T, Hogg JC, English D, et al. Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow. Am J Physiol Heart Circ Physiol. 2000;279(6):H2954-60.
71. Ash Z, Emery P. The role of tocilizumab in the management of rheumatoid arthritis. Expert Opin Biol Ther. 2012;12(9):1277-89.
72. Myasoedova E, Crowson CS, Kremers HM, et al. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis. 2010;69(7):1310-4.
73. van Hall G, Steensberg A, Sacchetti M, et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab. 2003;88(7):3005-10.
74. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy - analyses from a large US observational study. Arthritis Rheum. 2007;56(9):2886-95.
75. Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis. 2011;70:I104-8.
76. Li N, Grivennikov SI, Karin M. The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell. 2011;19(4):429-31.
77. Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology. 2012;51:V38-47.
78. Bernatsky S, Renoux C, Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures. Ann Rheum Dis. 2010;69(9):1691-3.
79. Burmester GR, Feist E, Kellner H, et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis. 2011;70(5):755-9.
80. Listing J, Strangfeld A, Rau R, et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low - results from RABBIT, the German biologics register. Arthritis Res Ther. 2006;8(3):R66.
81. Soliman MM, Ashcroft DM, Watson KD, et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70(4):583-9.
82. Kavanaugh A, Emery P, van Vollenhoven RF, et al. Tocilizumab monotherapy compared with adalimumab monotherapy in patients with rheumatoid arthritis: results of a 24-week study. Arthritis Rheum. 2012;64(10):S333-4.
83. Haque S, Mirjafari H, Bruce IN. Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Curr Opin Lipidol. 2008;19(4):338-43.
84. Kerola AM, Kauppi MJ, Kerola T, et al. How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear? Ann Rheum Dis. 2012;71(10):1606-15.